US 12251387
Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors
granted A61KA61K31/506A61K31/5377
Quick answer
US patent 12251387 (Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/506, A61K31/5377, A61K31/5386, A61P